Multiple myeloma: how did it begin?
- PMID: 8015334
- DOI: 10.1016/s0025-6196(12)61349-4
Multiple myeloma: how did it begin?
Abstract
Objective: To present a historical overview of multiple myeloma.
Design: The pertinent literature, from the early cases of this disorder to subsequent diagnostic advances, was reviewed.
Results: The first well-known case of multiple myeloma (described in the 1840s) was that of Mr. McBean, a highly respectable tradesman from London. Although the features of Bence Jones proteinuria were recognized by his physician, Dr. William Macintyre, urine specimens from Mr. McBean were studied in detail by Henry Bence Jones, a well-known chemical pathologist, who confirmed the findings of Macintyre. The disease was rarely recognized until 1889, when the famous case report by Kahler was published. Interestingly, the subject of this case report (Dr. Loos) survived for 8 years despite inadequate chemotherapy. The role of plasma cells was recognized at the turn of the century. In 1922, Bayne-Jones and Wilson identified two distinct groups of Bence Jones protein, but a relationship between Bence Jones protein and the serum proteins of multiple myeloma was not demonstrated until 1956, in a study performed by Korngold and Lipari. (The designation of the two main classes of Bence Jones protein as kappa and lambda is a tribute to these two investigators.) The major breakthrough was the discovery that light chains from a serum IgG myeloma protein and the Bence Jones protein from the same patient's urine were identical.
Conclusion: Multiple myeloma is a devastating disorder of plasma cell proliferation in the bone marrow that can result in skeletal destruction. Immunoelectrophoresis is useful as the initial diagnostic procedure.
Similar articles
-
[Who was Mr. McBean and what resulted from his death?].Vnitr Lek. 2000 Oct;46(10):732-5. Vnitr Lek. 2000. PMID: 11344636 Czech.
-
History of multiple myeloma.Recent Results Cancer Res. 2011;183:3-23. doi: 10.1007/978-3-540-85772-3_1. Recent Results Cancer Res. 2011. PMID: 21509678
-
Bence-Jones Protein.2023 Apr 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Apr 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31082079 Free Books & Documents.
-
A history of the kidney in plasma cell disorders.Contrib Nephrol. 2007;153:5-24. doi: 10.1159/000096757. Contrib Nephrol. 2007. PMID: 17075221 Review.
-
A historical perspective on milestones in multiple myeloma research.Eur J Haematol. 2018 Mar;100(3):221-228. doi: 10.1111/ejh.13003. Epub 2017 Dec 27. Eur J Haematol. 2018. PMID: 29194778 Review.
Cited by
-
Targeted proteomic strategy for clinical biomarker discovery.Mol Oncol. 2009 Feb;3(1):33-44. doi: 10.1016/j.molonc.2008.12.001. Epub 2008 Dec 11. Mol Oncol. 2009. PMID: 19383365 Free PMC article. Review.
-
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.Int J Mol Sci. 2019 Jun 10;20(11):2822. doi: 10.3390/ijms20112822. Int J Mol Sci. 2019. PMID: 31185596 Free PMC article. Review.
-
Multiple Myeloma (Part 1) - Update on Epidemiology, Diagnostic Criteria, Systemic Treatment and Prognosis.Rev Bras Ortop (Sao Paulo). 2023 Jun 29;58(3):361-367. doi: 10.1055/s-0043-1770149. eCollection 2023 Jun. Rev Bras Ortop (Sao Paulo). 2023. PMID: 37396092 Free PMC article.
-
A list of candidate cancer biomarkers for targeted proteomics.Biomark Insights. 2007 Feb 7;1:1-48. Biomark Insights. 2007. PMID: 19690635 Free PMC article.
-
Making Meaningful Clinical Use of Biomarkers.Biomark Insights. 2017 Jun 19;12:1177271917715236. doi: 10.1177/1177271917715236. eCollection 2017. Biomark Insights. 2017. PMID: 28659713 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical